BioCentury | Feb 21, 2018
Distillery Therapeutics

Cancer

...IFNγ-producing CD4 + T cells and CD8 + T cells and tumor levels of IFNγ, Tbet...
...3-like 1 cartilage glycoprotein-39 (CHI3L1; YKL40); twist homolog 1 (TWIST1); interferon γ (IFNγ); T-box 21 (Tbet; TBX21...
BioCentury | Dec 18, 2017
Preclinical News

IL-18 secreting CAR T cells enhance immune killing of tumors

...researchers screened for cytokines that induce a T cell expression signature of high T-box21 (Tbet; TBX21...
...with unmodified CAR T cells. Elizabeth S. Eaton University of Cologne Torque Therapeutics Inc. Forkhead box O1 (FOXO1) Interleukin-12 (IL-12) Interleukin-18 (IL-18) PD-1 T-box 21 (Tbet) (TBX21)...
BioCentury | Mar 14, 2017
Distillery Therapeutics

Autoimmune disease

...INDICATION: Lupus Mouse studies suggest inhibiting Tbet -expressing B cells could help treat systemic lupus erythematosus...
...normal Tbet expression. In two other genetic mouse models of lupus, B cell-specific knockout of Tbet...
...cells. Next steps include identifying inhibitors specific for Tbet- expressing B cells. TARGET/MARKER/PATHWAY: T-box 21 (Tbet; TBX21...
BioCentury | Feb 24, 2017
Clinical News

A T-cell gene signature in infants could predict Type I diabetes

...months of age (n=14). The signature was distinguished by several genes ( CCR6 , IL21, TBX21...
BioCentury | Oct 6, 2016
Product R&D

Local sensitivity

...PDCD1 ; CD279 ) - Programmed cell death 1 T-bet ( TBX21 ) - T-box 21...
BioCentury | Feb 19, 2015
Distillery Therapeutics

Therapeutics: RAR-related orphan receptor C thymus-specific isoform (RORγ2; RORγT); T-box 21 (TBX21; TBET)

...fusions between a protein transduction domain and the transcription modulation domains (TMD) of RORγT or TBET...
...comparable potency to an anti-interleukin-17 mAb. In a mouse model of RA, injection of the TBET-based...
...autoimmune diseases. TARGET/MARKER/PATHWAY: RAR-related orphan receptor C thymus-specific isoform (RORγ2; RORγT); T-box 21 ( TBX21 ; TBET...
BioCentury | Mar 5, 2012
Company News

Tibet Pharmaceuticals deal

...had $25.6 million in sales for the nine-months ended Sept. 30, 2011. Tibet Pharmaceuticals Inc. (NASDAQ:TBET...
BioCentury | Oct 3, 2011
Finance

Cost averaging down

...$177.5 $377.0 112% Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) 2/3/11 $42.0 $120.6 $171.1 42% Tibet Pharmaceuticals Inc. (NASDAQ:TBET...
BioCentury | Jul 4, 2011
Finance

3Q Financial Markets Preview: Hoping the rally has legs

...$177.5 $423.9 139% Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) 2/3/11 $42.0 $120.6 $206.4 71% Tibet Pharmaceuticals Inc. (NASDAQ:TBET...
BioCentury | Jun 20, 2011
Company News

Tibet Pharmaceuticals management update

...Tibet Pharmaceuticals Inc. (NASDAQ:TBET), Diqing, China Business: Pulmonary, Gastrointestinal, Genitourinary Departing: Taylor Guo as CEO; he...
Items per page:
1 - 10 of 14